JMJD1C: A Potential Drug Target Or Biomarker for Various Diseases

Target Name: JMJD1C

NCBI ID: G221037

JMJD1C

JMJD1C: A Potential Drug Target Or Biomarker for Various Diseases

JMJD1C (TRIP8) is a protein that is expressed in various tissues throughout the body, including the brain, pancreas, and gastrointestinal tract. It is a member of the superfamily of RNA-binding proteins, known as AP-1-like proteins (AP-1s), and is involved in various cellular processes, including cell signaling, DNA replication, and metabolism.

Recent studies have identified JMJD1C as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and gastrointestinal disorders. In this article, we will explore the biology and potential therapeutic applications of JMJD1C.

Structure and Function

JMJD1C is a 21-kDa protein that is composed of a unique catalytic domain and a long N-terminal region that contains a variety of functional domains, including a leucine-rich repeat (LRR), a conserved protein-coding DNA interaction domain, and a T-cell factor-4 (TCF4) interaction domain.

The catalytic domain of JMJD1C contains a unique ATP-binding site that is unique among AP-1-like proteins. This site is able to bind ATP with a high affinity and is critical for JMJD1C's catalytic activity.

The N-terminal region of JMJD1C contains a variety of functional domains, including a leucine-rich repeat (LRR), a conserved protein-coding DNA interaction domain, and a T-cell factor-4 (TCF4) interaction domain. The LRR is a unique feature that is found in a variety of AP-1-like proteins and is involved in protein-protein interactions. The conserved protein-coding DNA interaction domain is a common feature of AP-1-like proteins and is involved in DNA replication and repair. The TCF4 interaction domain is a unique feature that is found in a variety of proteins, including AP-1-like proteins, and is involved in cell signaling.

JMJD1C is expressed in a variety of tissues throughout the body, including the brain, pancreas, and gastrointestinal tract. It is involved in various cellular processes, including cell signaling, DNA replication, and metabolism.

Potential Therapeutic Applications

JMJD1C has been identified as a potential drug target or biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and gastrointestinal disorders.

In cancer, JMJD1C has been shown to be involved in the regulation of cell signaling, including the T cell signaling pathway. JMJD1C has been shown to play a role in the regulation of cell proliferation and has been identified as a potential therapeutic target for cancer.

In neurodegenerative diseases, JMJD1C has been shown to be involved in the regulation of neurotransmitter signaling and has been identified as a potential therapeutic target for neurodegenerative diseases.

In gastrointestinal disorders, JMJD1C has been shown to be involved in the regulation of inflammation and has been identified as a potential therapeutic target for gastrointestinal disorders.

Conclusion

JMJD1C is a unique protein that is involved in various cellular processes throughout the body. Recent studies have identified JMJD1C as a potential drug target or biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and gastrointestinal disorders. Further research is needed to fully understand the biology and potential therapeutic applications of JMJD1C.

Protein Name: Jumonji Domain Containing 1C

Functions: Probable histone demethylase that specifically demethylates 'Lys-9' of histone H3, thereby playing a central role in histone code. Demethylation of Lys residue generates formaldehyde and succinate. May be involved in hormone-dependent transcriptional activation, by participating in recruitment to androgen-receptor target genes (By similarity)

The "JMJD1C Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about JMJD1C comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets